<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201201218793N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-04-09</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Probiotics in the treatment of  Helicobacter Pylori infection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of antibiotic with antibiotic and probiotic combination in the eradication of  Helicobacter Pylori infection in children by a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9281</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>helicobacter pylori infection.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention  group Amoxicillin  (dose 50 mg / kg / day/divided in 2 doses) and Furazolidone (dose of 6 mg / kg / day/divided in 2 doses) for 1 week and Omeprazole for 4 weeks (with a dose of 1 mg / kg / day/once at morning) are prescribed. Amoxicillin and Furazolidone tablets or syrup forms based on the child's age are given. In addition, patients in this group receive probiotics for 2 weeks. The probiotic is named RESTORE, the product of Protexin company that contains 7 types of probiotics including Lactobacillus Acidophilus, Lactobacillus Rhamnosus, Lactobacillus Bulgaricus, Lactobacillus Casei, Streptococcus Thermophilus, Bifidobacterium Infantis(child specific), Bifidobacterium breve.&#13;
This product is given once daily after breakfast. Intervention 2: In the control  group Amoxicillin  (dose 50 mg / kg / day/divided in 2 doses) and Furazolidone (dose of 6 mg / kg / day/divided in 2 doses) for 1 week and Omeprazole for 4 weeks (with a dose of 1 mg / kg / day/once at morning) are prescribed. Amoxicillin and Furazolidone tablets or syrup forms based on the child's age are given.  In addition to the standard regimen, in the control group, the patients receive placebo in the first 2 weeks. Placebo is a product seeming just like the probiotic and is composed of dextrose. This product is prepared by Protexin company and is prescribed once daily after breakfast similar to the RESTORE  probiotic.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Shoaran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Endoscopy Ward, Children Medical Center Hospital,Qarib St, Keshavarz Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6692 4545</telephone>
        <email>maryamshoaran@yahoo.com; maryamshoaran1@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ahmad Khodadad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Endoscopy Ward, Children Medical Center Hospital, Qarib St, Keshavarz Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6692 4545</telephone>
        <email>khodadadmd@yahoo.com; ahmadkhodadad@gmail.com; khodadadmd@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:  more than 2 and less than 14 years of age; gastrointestinal symptoms including epigastric tenderness, abdominal pain at night, worsening of  abdominal pain by eating, early satiety, abdominal pain or weight loss without a known cause,  frequent vomiting and  Iron deficiency anemia;  confirmation of Helicobacter Pylori infection by rapid urease test or histopathology.&#13;
&#13;
Exclusion criteria:  use of proton pump inhibitors, H2 receptor antagonists, bismuth compounds and antibiotics  in the past 4 weeks;  history of surgery on the stomach; sensitivity to certain types of antibiotics; G6PD  enzyme deficiency(in these patients  the use of furazolidone may lead to anemia ); known underlying disease including renal failure, heart disease or endocrine disease.</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B98.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Helicobacter pylori [H.pylori] as the cause of diseases classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention  group Amoxicillin  (dose 50 mg / kg / day/divided in 2 doses) and Furazolidone (dose of 6 mg / kg / day/divided in 2 doses) for 1 week and Omeprazole for 4 weeks (with a dose of 1 mg / kg / day/once at morning) are prescribed. Amoxicillin and Furazolidone tablets or syrup forms based on the child's age are given. In addition, patients in this group receive probiotics for 2 weeks. The probiotic is named RESTORE, the product of Protexin company that contains 7 types of probiotics including Lactobacillus Acidophilus, Lactobacillus Rhamnosus, Lactobacillus Bulgaricus, Lactobacillus Casei, Streptococcus Thermophilus, Bifidobacterium Infantis(child specific), Bifidobacterium breve.&#13;
This product is given once daily after breakfast.</i_keyword>
      <i_keyword>In the control  group Amoxicillin  (dose 50 mg / kg / day/divided in 2 doses) and Furazolidone (dose of 6 mg / kg / day/divided in 2 doses) for 1 week and Omeprazole for 4 weeks (with a dose of 1 mg / kg / day/once at morning) are prescribed. Amoxicillin and Furazolidone tablets or syrup forms based on the child's age are given.  In addition to the standard regimen, in the control group, the patients receive placebo in the first 2 weeks. Placebo is a product seeming just like the probiotic and is composed of dextrose. This product is prepared by Protexin company and is prescribed once daily after breakfast similar to the RESTORE  probiotic.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Eradication rate of helicobacter pylori. Timepoint: after two months of the treatment. Method of measurement: stool antigen for helicobacter pylori.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Endoscopic finding. Timepoint: at the time of endoscopy. Method of measurement: by the report of the person performing the endoscopy.</sec_outcome>
      <sec_outcome>Adverse effects of the drugs. Timepoint: during the course of treatment. Method of measurement: subjective /asking the patients and parents.</sec_outcome>
      <sec_outcome>Concordance of the result of rapid urease test and pathology report. Timepoint: after the pathology report is prepared. Method of measurement: The comparison of the result of urease test with histopathological report by the researchers.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-01-28</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>Headquarter for Tehran University of Medical Sciences, On the Corner of Keshavarz Blvd. and Qods Street, Keshavarz Blvd., Vali-e-Asr Square, Tehran, Iran. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
